Eurofins-Cerep SA Overview
Pro stress-test →Eurofins-Cerep provides drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies globally, with research services including compound management and high-throughput screening and profiling. The company uses its BioPrint technology systems to analyze pharmaceutical drugs and build predictive models of new drug potential.
Strategic Profile
Pro stress-test →As a subsidiary of Eurofins Discovery Services LUX Holding SARL, Eurofins-Cerep is part of a larger group specializing in pharmaceutical discovery services. The company maintains a strong balance sheet with low debt and substantial cash reserves, positioning itself as a specialized provider in the pre-clinical drug research market.
Competitive Landscape
Pro stress-test →Eurofins-Cerep competes in the drug discovery outsourcing market against larger integrated CROs and specialized discovery service providers. The company differentiates through its BioPrint proprietary technology for pharmacological profiling. As part of the broader Eurofins Scientific group, it benefits from cross-selling opportunities while competing against standalone discovery specialists and larger pharmaceutical services companies.
Industry Context
Eurofins-Cerep SA operates in Diagnostics & Research / Pharmaceutical Discovery Services.
Key facts
Founded: 1989 · Headquarters: Celle-Lévescault, France · Employees: 228 · Revenue: €40.49M · Market cap: €91.80M